Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,674.00
Bid: 1,686.00
Ask: 1,692.00
Change: -26.00 (-1.53%)
Spread: 6.00 (0.356%)
Open: 1,678.00
High: 1,722.00
Low: 1,674.00
Prev. Close: 1,700.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Appointment

7 May 2009 07:00

RNS Number : 8018R
Genus PLC
07 May 2009
 



For immediate release 7 May 2009

Genus plc

('Genus' or 'the Company')

Board Appointment

Genus, a leading global animal genetics company, is pleased to announce the appointment of Mike Buzzacott as a non-executive director.

Mike Buzzacott spent 34 years at BP prior to his retirement in 2004, holding a number of international roles including Finance & Control Director Asia Pacific, CFO BP Nutrition and Group Vice President Petrochemicals. He is currently a non-executive director and Audit Committee chairman of Rexam Plc (retiring in May 2009) and Croda Plc. He is also a non-executive director of Scapa Plc. He was Chairman of Biofuels Plc from 2006 until its re-registration in 2007 as a private company.

Mike Buzzacott will chair the Company's Audit Committee and will be a member of the Remuneration Committee.

Commenting on the appointment, John Hawkins, Chairman of Genus, said:

"We are delighted to welcome Mike to the Board. He brings with him considerable experience gained in overseas international markets that will greatly benefit Genus during its next stage of strategic development and beyond."

There are no further details to be disclosed in respect of Mike Buzzacott under paragraph 9.6.13R of the Listing Rules of the UK Financial Services Authority.

For further information please contact:

Genus plc Tel: 01256 345970

John Hawkins, Chairman

Richard Wood, Chief Executive

Buchanan Communications Tel: 0207 466 5000

Charles Ryland , Isabel Podda

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. It's non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain. 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOACKAKDPBKDDPK
Date   Source Headline
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding
1st Oct 20182:00 pmRNSTotal Voting Rights
24th Sep 20186:01 pmRNSAdditional Listing
24th Sep 20181:52 pmRNSNon-Executive Director Retirement
19th Sep 20183:36 pmRNSDirector/PDMR Shareholding
18th Sep 20185:21 pmRNSDirector/PDMR Shareholding
17th Sep 20185:27 pmRNSDirector/PDMR Shareholding
6th Sep 20187:00 amRNSPreliminary Results
1st Aug 20182:00 pmRNSBlock listing Interim Review
20th Jul 201811:56 amRNSHolding(s) in Company
11th Jul 20181:44 pmRNSHolding(s) in Company
9th Jul 20187:00 amRNSHolding(s) in Company
20th Jun 20187:00 amRNSCapital Markets Event
12th Jun 20182:42 pmRNSDirector/PDMR Shareholding
24th May 20187:00 amRNSBoard Appointment
18th May 20185:22 pmRNSDirector/PDMR Shareholding
1st May 20184:39 pmRNSTotal Voting Rights
12th Apr 20186:18 pmRNSDirector/PDMR Shareholding
16th Mar 20182:34 pmRNSDirector/PDMR Shareholding
5th Mar 20186:38 pmRNSDirector/PDMR Shareholding
1st Mar 201810:48 amRNSHolding(s) in Company
28th Feb 20187:00 amRNSInterim Results
1st Feb 20182:00 pmRNSBlock listing Interim Review
29th Dec 201711:51 amRNSDirector/PDMR Shareholding
22nd Dec 201711:27 amRNSDirector/PDMR Shareholding
13th Dec 20175:48 pmRNSDirector/PDMR Shareholding
8th Dec 20174:41 pmRNSDirector/PDMR Shareholding
1st Dec 20172:00 pmRNSTotal Voting Rights
23rd Nov 201710:57 amRNSDirector/PDMR Shareholding
17th Nov 20172:15 pmRNSAdditional Listing to Correct Discrepancy
16th Nov 20172:49 pmRNSResult of AGM
16th Nov 20177:00 amRNSAGM Trading Update
6th Nov 201712:48 pmRNSDirector/PDMR Shareholding
2nd Nov 20172:01 pmRNSNon-Executive Director Retirement
1st Nov 20172:00 pmRNSTotal Voting Rights
31st Oct 20177:00 amRNSAdditional Listing
12th Oct 201710:39 amRNSNotice of AGM
2nd Oct 20172:00 pmRNSTotal Voting Rights
29th Sep 20177:08 amRNSDirector Declaration
21st Sep 20175:29 pmRNSDirector/PDMR Shareholding - Replacement
14th Sep 20175:30 pmRNSDirector/PDMR Shareholding
7th Sep 20177:00 amRNSPreliminary Results
1st Sep 20173:12 pmRNSTotal Voting Rights
17th Aug 20172:51 pmRNSHolding(s) in Company
1st Aug 20172:00 pmRNSBlock listing Interim Review
1st Aug 20172:00 pmRNSTotal Voting Rights
3rd Jul 20172:59 pmRNSTotal Voting Rights
29th Jun 20175:23 pmRNSAdditional Listing
12th Jun 20173:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.